Epithelial-myoepithelial carcinoma (EMC) can be a challenging diagnosis due to a lack of obvious invasion and bland cytology. We report an unusual case of a low-grade EMC with prominent fibrous stroma, an extensive solid-oncocytic differentiation and limited areas of morphological clearly identifiable characteristic biphasic (tubular) differentiation, clear cells and PAS-positive secretions/calcifications. Both areas were investigated by next generation sequencing (Oncomine comprehensive assay) and revealed a typical concordant HRAS p.Q61R mutation. An additional heterogeneous ARID1A (p.E672*) terminating mutation with loss of heterozygosity, which could be visualized predominantly in the solid-oncocytic differentiation by immunohistochemical loss of ARID1A protein expression, was found. This is the first case of an EMC of the salivary gland to be described with two separate tumor clones involving concordant HRAS and heterogeneous ARID1A mutations. The latter seem to be a "second hit" and was predominantly found in the solid-oncocytic differentiation, suggesting a potential morpho-molecular association.

Department of Otorhinolaryngology Head and Neck Surgery University Hospital Zurich Zurich Switzerland

Department of Pathology and Molecular Pathology University Hospital Zurich Schmelzbergstr 12 8091 Zurich Switzerland

Institute of Pathology Enge Zurich Switzerland

Sikl's Department of Pathology Faculty of Medicine in Plzen Charles University Pilsen Czech Republic

University of Zurich Zurich Switzerland

See more in PubMed

Seethala RR, Barnes EL, Hunt JL. Epithelial-myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aerodigestive tract. Am J Surg Pathol. 2007;31(1):44–57. doi: 10.1097/01.pas.0000213314.74423.d8. PubMed DOI

Yang GC, Soslow RA. Epithelial-myoepithelial carcinoma of the parotid. A case of ductal-predominant presentation with cytologic, histologic and ultrastructural correlations. Acta Cytol. 1999;43(6):1113–1118. doi: 10.1159/000331363. PubMed DOI

El Hallani S, Udager AM, Bell D, Fonseca I, Thompson LDR, Assaad A, et al. Epithelial-myoepithelial carcinoma: frequent morphologic and molecular evidence of preexisting pleomorphic adenoma, common HRAS mutations in PLAG1-intact and HMGA2-intact cases, and occasional TP53, FBXW7, and SMARCB1 alterations in high-grade cases. Am J Surg Pathol. 2018;42(1):18–27. doi: 10.1097/PAS.0000000000000933. PubMed DOI PMC

Seethala RR, Richmond JA, Hoschar AP, Barnes EL. New variants of epithelial-myoepithelial carcinoma: oncocytic-sebaceous and apocrine. Arch Pathol Lab Med. 2009;133(6):950–959. doi: 10.1043/1543-2165-133.6.950. PubMed DOI

Seethala RR. Oncocytic and apocrine epithelial myoepithelial carcinoma: novel variants of a challenging tumor. Head Neck Pathol. 2013;7(Suppl 1):S77–S84. doi: 10.1007/s12105-013-0461-0. PubMed DOI PMC

Chiosea SI, Miller M, Seethala RR. HRAS mutations in epithelial-myoepithelial carcinoma. Head Neck Pathol. 2014;8(2):146–150. doi: 10.1007/s12105-013-0506-4. PubMed DOI PMC

Urano M, Nakaguro M, Yamamoto Y, Hirai H, Tanigawa M, Saigusa N, et al. Diagnostic significance of HRAS mutations in epithelial-myoepithelial carcinomas exhibiting a broad histopathologic spectrum. Am J Surg Pathol. 2019 doi: 10.1097/PAS.0000000000001258. PubMed DOI

Geyer FC, Li A, Papanastasiou AD, Smith A, Selenica P, Burke KA, et al. Recurrent hotspot mutations in HRAS Q61 and PI3 K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nat Commun. 2018;9(1):1816. doi: 10.1038/s41467-018-04128-5. PubMed DOI PMC

Pareja F, Geyer FC, Brown DN, Sebastiao APM, Gularte-Merida R, Li A, et al. Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. NPJ Breast Cancer. 2019;5:6. doi: 10.1038/s41523-018-0101-7. PubMed DOI PMC

Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013;3(1):35–43. doi: 10.1158/2159-8290.CD-12-0361. PubMed DOI PMC

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–1543. doi: 10.1056/NEJMoa1008433. PubMed DOI PMC

Weinreb I, Zhang L, Tirunagari LM, Sung YS, Chen CL, Perez-Ordonez B, et al. Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer. 2014;53(10):845–856. doi: 10.1002/gcc.22195. PubMed DOI

Sebastiao APM, Pareja F, Kumar R, Brown DN, Silveira C, da Silva EM, et al. Genomic analysis of recurrences and high-grade forms of polymorphous adenocarcinomas. Histopathology. 2019 doi: 10.1111/his.13854. PubMed DOI PMC

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–713. doi: 10.1038/nm.4333. PubMed DOI PMC

Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228–231. doi: 10.1126/science.1196333. PubMed DOI PMC

Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837. doi: 10.1038/ncomms13837. PubMed DOI PMC

Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5(7):752–767. doi: 10.1158/2159-8290.CD-14-0849. PubMed DOI PMC

Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of ARID1A expression sensitizes cancer cells to PI3 K- and AKT-inhibition. Oncotarget. 2014;5(14):5295–5303. doi: 10.18632/oncotarget.2092. PubMed DOI PMC

Atypical and worrisome histological features in pleomorphic adenoma: challenging and potentially significant diagnostic pitfall

SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets